Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caris Life SciencesCAI -0.89%11 EBITDA Margin % is 7.97% as of Mar. 2026. GuruFocus rates CAI with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Caris Life Sciences ranks better than 76.91% on this metric.
Caris Life Sciences (NAS:CAI) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Caris Life Sciences EBITDA Margin % Related Terms
Caris Life Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Caris Life Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI vs DNTH, MANE, TNGX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Caris Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caris Life Sciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caris Life Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Caris Life Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caris Life Sciences (CAI) has a EBITDA Margin % of 7.97% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Caris Life Sciences and its competitors. According to the industry distribution chart, Caris Life Sciences ranks #217 out of 940 companies in the Biotechnology industry, placing it in the top 23.1%.
Is Caris Life Sciences' EBITDA Margin % too high?
Caris Life Sciences' current EBITDA Margin % is 7.97%. Based on the distribution chart, Caris Life Sciences ranks #217 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Caris Life Sciences has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' EBITDA Margin % compare to DNTH and MANE?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #217 out of 940 companies for EBITDA Margin %. This places Caris Life Sciences in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Caris Life Sciences and its competitors. Caris Life Sciences's current EBITDA Margin % is 7.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current EBITDA Margin % of 7.97%. The current EBITDA Margin % is 7.97%. Caris Life Sciences' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current EBITDA Margin % is 7.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
11GF Score
Get the complete analysis for CAI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI has been successfully added to your 
